The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | Key lung cancer updates: KRAS(G12C) inhibitors and ADCs
Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses key areas of interest in the field of lung cancer treatment, in particular focusing on the KRAS(G12C) inhibitors, AMG 510 and MRTX849 (adagrasib). MRTX849 is currently being trialled in combination with doxcetaxel in the KRYSTAL-12 trial (NCT04685135) and AMG 510 is being trialled in combination with doxcetaxel in the CodeBreak 200 trial (NCT04303780). Furthermore, Dr Johnson discusses the increasing number of trials of tyrosine kinase inhibitors targeting HER2 in lung cancer and promising trials involving antibody-drug conjugates. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
